- Ongoing, recruitingTherapeutic exploratory (Phase II)
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study
This study is testing new treatments for a type of cancer called anal cancer that has spread. It combines existing chemotherapy with an investigational drug and radiotherapy to see if patients live longer without their cancer getting worse.
For: metastatic squamous cell anal carcinomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR)
This study is testing a new combination of treatments for stomach cancer that can be removed with surgery. It combines a new drug, spartalizumab, with a standard chemotherapy (FLOT). Researchers want to see if this new combination helps shrink the cancer more before surgery and improves outcomes.
For: Resectable Gastric CancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
SOLTI-1904: EfficACy of tislelizumab and spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial)
This study, called ACROPOLI, is testing new treatments for advanced cancer that has spread. It focuses on how well these treatments shrink tumours in patients whose cancers have a specific genetic marker. The main goal is to see if the treatments work, and how they affect patients' lives.
For: Metastatic diseaseSpain